Bridgeway Capital Management LLC Sells 227,387 Shares of OptiNose, Inc. (NASDAQ:OPTN)

Bridgeway Capital Management LLC lowered its position in OptiNose, Inc. (NASDAQ:OPTN) by 93.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,713 shares of the company’s stock after selling 227,387 shares during the period. Bridgeway Capital Management LLC owned about 0.16% of OptiNose worth $105,000 at the end of the most recent reporting period.

Separately, Acorn Capital Advisors LLC bought a new stake in shares of OptiNose in the fourth quarter worth $2,824,000. Institutional investors and hedge funds own 85.60% of the company’s stock.

Wall Street Analysts Forecast Growth

OPTN has been the subject of several research analyst reports. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price objective (down previously from $18.00) on shares of OptiNose in a report on Friday, March 21st. Lake Street Capital lowered OptiNose from a “buy” rating to a “hold” rating and cut their price objective for the stock from $17.00 to $9.00 in a report on Thursday, March 20th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $9.00 price objective (down previously from $15.00) on shares of OptiNose in a report on Friday, March 21st.

OptiNose Stock Up 0.3%

Shares of OPTN opened at $9.45 on Wednesday. The business has a 50-day simple moving average of $8.47 and a two-hundred day simple moving average of $7.46. The stock has a market cap of $95.70 million, a price-to-earnings ratio of -2.25 and a beta of -0.88. OptiNose, Inc. has a 52 week low of $4.82 and a 52 week high of $20.03.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.67. The company had revenue of $21.47 million during the quarter, compared to analysts’ expectations of $21.02 million. On average, equities analysts anticipate that OptiNose, Inc. will post -3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 8,213 shares of company stock worth $43,643 over the last quarter. 2.30% of the stock is currently owned by corporate insiders.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.